Efficacy and Safety Study of Fluticasone/Salmeterol Administered With Elpenhaler

Elpen Pharmaceutical Co. Inc.42 enrolled

Overview

The aim of this study is to establish the therapeutic equivalence between the test (Fluticasone/Salmeterol administered with Elpenhaler®db, Rolenium®) and the reference formulation (Seretide®, administered with Diskus®), both containing 250/50μg of the Fluticasone/Salmeterol combination. In case of inhaled products, it is not possible to follow the classic scheme, based on similarity of plasma concentration-time behavior of parent drug in assessing bioequivalence.

A pharmacodynamic study was designed in order to assess the therapeutic equivalence of the new formulation of Fluticasone/Salmeterol with the innovative one. The test and reference Fluticasone/Salmeterol formulations will be compared in terms of their bronchodilator effects in lung function. Forced Expiratory Volume in 1 second (FEV1) will be the primary efficacy measure and will be measured in such a way that a similar time-dependent increase in pulmonary function can be demonstrated for both Fluticasone/Salmeterol formulations in patients with asthma. In terms of safety comparison, repeated measurements of adverse events, vital signs, heart rate, blood hematology and biochemistry as well as ECG changes will enable the establishment of the similar safety profile of the test and reference Fluticasone/Salmeterol combinations. The study will be conducted in a randomized, double-blind, double-dummy, placebo-controlled, 3x3 crossover fashion.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

DOUBLE

Enrollment

Conditions

Asthma

Interventions

RP - TADEVICE

randomized, double-blind, double-dummy, placebo-controlled, 3-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol combination administered with Elpenhaler®db (Rolenium®) versus the innovative one (Seretide Diskus®)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age 18-65 years, * diagnosis of asthma of 6 months, * FEV1 ≥ 50% and ≤ 80% predicted, reversibility of at least 12%, * stable asthma for at least 4 weeks, * inhaled steroids (ICS) at a stable dose within the previous 30 days, * PIF 30 - 90 lt/min and * informed consent. Exclusion Criteria: * history of other pulmonary disease, asthma exacerbation or respiratory infection within the previous 4 weeks, * hospitalization for acute asthmatic symptoms requiring parenteral steroids or oral steroid dose increase within the previous 30 days, * heavy smokers, * change of asthma medication within the previous 4 weeks, seasonal asthma alone, * history of severe heart disease, * pregnancy or lactation, * use of a β-blocker, of a NSAID or an antiallergic/antihistaminic medication within 2 weeks prior to screening visit.

Outcomes

Primary Outcomes

FEV1

12-hour average FEV1

Time frame: 8 days

Secondary Outcomes

Adverse Events

Number of Adverse Events during the study

Time frame: 8 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.